IMFINZI-Based Treatment Before and After Surgery Reduced the Risk of Disease Recurrence, Progression Events or Death by 32% in Resectable Non-Small Cell Lung Cancer in the AEGEAN Phase III Trial
April 17, 2023
April 17, 2023
WILMINGTON, Delaware, April 17 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release on April 16, 2023:
Positive results from the AEGEAN Phase III trial showed that treatment with AstraZeneca's IMFINZI(R) (durvalumab) in combination with neoadjuvant chemotherapy before surgery and as adjuvant monotherapy after surgery led to a statistically significant and clinically meaningful improvement in event-free survival (EFS) versus neoadjuvant chemotherapy . . .
Positive results from the AEGEAN Phase III trial showed that treatment with AstraZeneca's IMFINZI(R) (durvalumab) in combination with neoadjuvant chemotherapy before surgery and as adjuvant monotherapy after surgery led to a statistically significant and clinically meaningful improvement in event-free survival (EFS) versus neoadjuvant chemotherapy . . .